These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23759657)

  • 21. Polypharmacy in heart failure - Is reducing medication safe?
    Hopper I; Skiba M; Windebank E; Brack J; Tonkin A; Krum H
    Int J Cardiol; 2016 Jul; 214():529-30. PubMed ID: 26837864
    [No Abstract]   [Full Text] [Related]  

  • 22. Lower cardiovascular mortality with atorvastatin and rosuvastatin vs simvastatin: Data from "moderate-intensity" statin users in an observational registry on chronic heart failure (Daunia Heart Failure Registry).
    Brunetti ND; Correale M; Totaro A; Ferraretti A; Monaco I; Passero T; De Gennaro L; Di Biase M
    Int J Cardiol; 2015 Sep; 194():23-7. PubMed ID: 26005803
    [No Abstract]   [Full Text] [Related]  

  • 23. Xanthine-oxidase inhibitors and statins in chronic heart failure: effects on vascular and functional parameters.
    Greig D; Alcaino H; Castro PF; Garcia L; Verdejo HE; Navarro M; López R; Mellado R; Tapia F; Gabrielli LA; Nogerol C; Chiong M; Godoy I; Lavandero S
    J Heart Lung Transplant; 2011 Apr; 30(4):408-13. PubMed ID: 21145258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Present status of various inotropic agents in heart failure.
    Mittal SR; Maheshwari N
    J Assoc Physicians India; 2001 Nov; 49():1095-9. PubMed ID: 11868865
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group.
    Feldman AM; Bristow MR; Parmley WW; Carson PE; Pepine CJ; Gilbert EM; Strobeck JE; Hendrix GH; Powers ER; Bain RP
    N Engl J Med; 1993 Jul; 329(3):149-55. PubMed ID: 8515787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose dependence of chronic positive inotropic effect of vesnarinone in patients with congestive heart failure due to idiopathic or ischemic cardiomyopathy.
    Kass DA; Van Anden E; Becker LC; Kasper EK; White WB; Feldman AM
    Am J Cardiol; 1996 Sep; 78(6):652-6. PubMed ID: 8831399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anticoagulants, antiplatelets, and statins in heart failure.
    Farmakis D; Filippatos G; Lainscak M; Parissis JT; Anker SD; Kremastinos DT
    Cardiol Clin; 2008 Feb; 26(1):49-58, vi. PubMed ID: 18312905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic heart failure and the quality of life.
    Alhaddad IA
    N Engl J Med; 1999 May; 340(19):1511-2. PubMed ID: 10328721
    [No Abstract]   [Full Text] [Related]  

  • 29. Importance of assessing changes in ventricular response to atrial fibrillation during evaluation of new heart failure therapies: experience from trials of flosequinan.
    Massie BM; Shah NB; Pitt B; Packer M
    Am Heart J; 1996 Jul; 132(1 Pt 1):130-6. PubMed ID: 8701855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New oral drugs for the treatment of congestive heart failure].
    Hayashida W; Kumada T; Kawai C
    Nihon Rinsho; 1992 Feb; 50(2):413-9. PubMed ID: 1319514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of rosuvastatin on fatigue in patients with heart failure.
    Perez AC; Jhund P; Preiss D; Kjekshus J; McMurray JJ
    J Am Coll Cardiol; 2013 Mar; 61(10):1121-2. PubMed ID: 23473415
    [No Abstract]   [Full Text] [Related]  

  • 32. Statins: a treatment option for chronic heart failure?
    von Haehling S; Okonko DO; Anker SD
    Heart Fail Monit; 2004; 4(3):90-7. PubMed ID: 15772704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Do positive inotropic agents adversely affect the survival of patients with chronic congestive heart failure? I. Introduction.
    Cody RJ
    J Am Coll Cardiol; 1988 Aug; 12(2):559-61. PubMed ID: 3392348
    [No Abstract]   [Full Text] [Related]  

  • 34. Chronic Inotropic Therapy in the Current Era: Old Wines With New Pairings.
    Pinney SP; Stevenson LW
    Circ Heart Fail; 2015 Sep; 8(5):843-6. PubMed ID: 26374915
    [No Abstract]   [Full Text] [Related]  

  • 35. Chronic heart failure and the quality of life.
    Pritzker MR
    N Engl J Med; 1999 May; 340(19):1511; author reply 1512. PubMed ID: 10328720
    [No Abstract]   [Full Text] [Related]  

  • 36. Statins and heart failure.
    Athyros VG; Karagiannis A; Mikhailidis DP
    J Am Coll Cardiol; 2010 Apr; 55(15):1644-5; author reply 1646. PubMed ID: 20378087
    [No Abstract]   [Full Text] [Related]  

  • 37. Optimal windows of statin use for immediate infarct limitation: 5'-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase.
    Sanada S; Asanuma H; Minamino T; Node K; Takashima S; Okuda H; Shinozaki Y; Ogai A; Fujita M; Hirata A; Kim J; Asano Y; Mori H; Tomoike H; Kitamura S; Hori M; Kitakaze M
    Circulation; 2004 Oct; 110(15):2143-9. PubMed ID: 15451788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tailored treatment for heart failure.
    Shibata M; Perez de Arenaza D
    Lancet; 2000 Aug; 356(9230):686. PubMed ID: 10968472
    [No Abstract]   [Full Text] [Related]  

  • 39. Letters to the editors.
    Angerstein RL; Lemberg L; Keller KB
    Am J Crit Care; 2005 Nov; 14(6):468; author reply 468-9. PubMed ID: 16249574
    [No Abstract]   [Full Text] [Related]  

  • 40. Oral milrinone in severe chronic heart failure.
    Feldman AM; Baughman KL; Strobeck JE
    N Engl J Med; 1992 Jun; 326(23):1565-6; author reply 1567. PubMed ID: 1579142
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.